115 related articles for article (PubMed ID: 15760062)
1. Liposomal amikacin dry powder inhaler: effect of fines on in vitro performance.
Shah SP; Misra A
AAPS PharmSciTech; 2004 Aug; 5(4):e65. PubMed ID: 15760062
[TBL] [Abstract][Full Text] [Related]
2. Liposomal amphotericin B dry powder inhaler: effect of fines on in vitro performance.
Shah SP; Misra A
Pharmazie; 2004 Oct; 59(10):812-3. PubMed ID: 15544064
[TBL] [Abstract][Full Text] [Related]
3. Development of liposomal amphotericin B dry powder inhaler formulation.
Shah SP; Misra A
Drug Deliv; 2004; 11(4):247-53. PubMed ID: 15371106
[TBL] [Abstract][Full Text] [Related]
4. Effect of interactive ternary mixtures on dispersion characteristics of ipratropium bromide in dry powder inhaler formulations.
Beilmann B; Kubiak R; Grab P; Häusler H; Langguth P
AAPS PharmSciTech; 2007 Apr; 8(2):Article 31. PubMed ID: 17622109
[TBL] [Abstract][Full Text] [Related]
5. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
[TBL] [Abstract][Full Text] [Related]
6. The relationship between drug concentration, mixing time, blending order and ternary dry powder inhalation performance.
Jones MD; Santo JG; Yakub B; Dennison M; Master H; Buckton G
Int J Pharm; 2010 May; 391(1-2):137-47. PubMed ID: 20211715
[TBL] [Abstract][Full Text] [Related]
7. Development of liposomal salbutamol sulfate dry powder inhaler formulation.
Huang WH; Yang ZJ; Wu H; Wong YF; Zhao ZZ; Liu L
Biol Pharm Bull; 2010; 33(3):512-7. PubMed ID: 20190418
[TBL] [Abstract][Full Text] [Related]
8. Dispersibility of lactose fines as compared to API in dry powders for inhalation.
Thalberg K; Åslund S; Skogevall M; Andersson P
Int J Pharm; 2016 May; 504(1-2):27-38. PubMed ID: 26965200
[TBL] [Abstract][Full Text] [Related]
9. The influence of lactose carrier on the content homogeneity and dispersibility of beclomethasone dipropionate from dry powder aerosols.
Zeng XM; Pandhal KH; Martin GP
Int J Pharm; 2000 Mar; 197(1-2):41-52. PubMed ID: 10704792
[TBL] [Abstract][Full Text] [Related]
10. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
Zeng XM; MacRitchie HB; Marriott C; Martin GP
Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
[TBL] [Abstract][Full Text] [Related]
11. Modeling dispersion of dry powders for inhalation. The concepts of total fines, cohesive energy and interaction parameters.
Thalberg K; Berg E; Fransson M
Int J Pharm; 2012 May; 427(2):224-33. PubMed ID: 22349053
[TBL] [Abstract][Full Text] [Related]
12. Lactose as a carrier in dry powder formulations: the influence of surface characteristics on drug delivery.
Zeng XM; Martin GP; Marriott C; Pritchard J
J Pharm Sci; 2001 Sep; 90(9):1424-34. PubMed ID: 11745794
[TBL] [Abstract][Full Text] [Related]
13. Liposomal budesonide for dry powder inhaler: preparation and stabilization.
Joshi MR; Misra A
AAPS PharmSciTech; 2001 Nov; 2(4):25. PubMed ID: 14727862
[TBL] [Abstract][Full Text] [Related]
14. Effects of mild processing pressures on the performance of dry powder inhaler formulations for inhalation therapy. 1: Budesonide and lactose.
Marek SR; Donovan MJ; Smyth HD
Eur J Pharm Biopharm; 2011 May; 78(1):97-106. PubMed ID: 21182942
[TBL] [Abstract][Full Text] [Related]
15. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
Le VN; Bierend H; Robins E; Steckel H; Flament MP
Int J Pharm; 2012 Jan; 422(1-2):75-82. PubMed ID: 22036653
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis.
Chennakesavulu S; Mishra A; Sudheer A; Sowmya C; Suryaprakash Reddy C; Bhargav E
Asian J Pharm Sci; 2018 Jan; 13(1):91-100. PubMed ID: 32104382
[TBL] [Abstract][Full Text] [Related]
17. Nano-liposomal dry powder inhaler of Amiloride Hydrochloride.
Chougule MB; Padhi BK; Misra A
J Nanosci Nanotechnol; 2006; 6(9-10):3001-9. PubMed ID: 17048511
[TBL] [Abstract][Full Text] [Related]
18. Dry powder inhalation of liposomal Ketotifen fumarate: formulation and characterization.
Joshi M; Misra A
Int J Pharm; 2001 Jul; 223(1-2):15-27. PubMed ID: 11451628
[TBL] [Abstract][Full Text] [Related]
19. An investigation into the dispersion mechanisms of ternary dry powder inhaler formulations by the quantification of interparticulate forces.
Jones MD; Hooton JC; Dawson ML; Ferrie AR; Price R
Pharm Res; 2008 Feb; 25(2):337-48. PubMed ID: 17952568
[TBL] [Abstract][Full Text] [Related]
20. New mechanisms to explain the effects of added lactose fines on the dispersion performance of adhesive mixtures for inhalation.
Grasmeijer F; Lexmond AJ; van den Noort M; Hagedoorn P; Hickey AJ; Frijlink HW; de Boer AH
PLoS One; 2014; 9(1):e87825. PubMed ID: 24489969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
